PTI - Proteostasis Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.09
+0.16 (+3.25%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.93
Open4.89
Bid0.00 x 1000
Ask0.00 x 1200
Day's Range4.89 - 5.32
52 Week Range1.71 - 10.38
Volume460,583
Avg. Volume2,694,173
Market Cap250.216M
Beta (3Y Monthly)-3.39
PE Ratio (TTM)N/A
EPS (TTM)-1.75
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.80
Trade prices are not sourced from all markets
  • Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
    Zacks15 days ago

    Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed

    Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.

  • PR Newswire22 days ago

    Proteostasis Therapeutics to Participate in Upcoming Investor Conferences

    BOSTON , Nov. 21, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to ...

  • Is the Options Market Predicting a Spike in Proteostasis Therapeutics (PTI) Stock?
    Zacks24 days ago

    Is the Options Market Predicting a Spike in Proteostasis Therapeutics (PTI) Stock?

    Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.

  • Proteostasis Therapeutics (PTI) Reports Q3 Loss, Tops Revenue Estimates
    Zackslast month

    Proteostasis Therapeutics (PTI) Reports Q3 Loss, Tops Revenue Estimates

    Proteostasis (PTI) delivered earnings and revenue surprises of -8.70% and 27.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Will Proteostasis Therapeutics (PTI) Report Negative Earnings Next Week? What You Should Know
    Zackslast month

    Will Proteostasis Therapeutics (PTI) Report Negative Earnings Next Week? What You Should Know

    Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for Lexington Realty Trust, Proteostasis Therapeutics, PDC Energy, Twenty-First Century Fox, Square, and Sabra Healthcare REIT — Fundamental Analysis, Key Performance Indications

    NEW YORK, Oct. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswire2 months ago

    Proteostasis Therapeutics Prices Public Offering of Common Stock

    BOSTON, Oct. 23, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today that it has priced an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.75 per share. The gross proceeds to Proteostasis from the offering, before underwriting discounts and commissions and offering costs, are expected to be approximately $74.3 million.  Proteostasis has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock. All of the shares to be sold in the offering are being sold by Proteostasis.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks None of the stocks hit 52-week highs in Monday's session. Down In The Dumps (Biotech stocks hitting 52-week ...

  • PR Newswire2 months ago

    Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock

    BOSTON, Oct. 22, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today that it intends to offer and sell, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering. As part of this offering, Proteostasis intends to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock.  All of the shares to be sold in the offering are to be sold by Proteostasis. Leerink Partners, Piper Jaffray & Co. and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering.

  • 5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout
    InvestorPlace2 months ago

    5 Low-Priced Biotech Stocks to Take Advantage of the Market Rout

    As we recently mentioned, biotech stocks have been particularly hammered over the last few weeks. Unfortunately, that’s meant that many biotech stocks have been hit hard. The market rout has caused many biotech stocks to drop to single or low double-digit prices.

  • Why Proteostasis Therapeutics Tumbled 23.2% on Friday
    Motley Fool2 months ago

    Why Proteostasis Therapeutics Tumbled 23.2% on Friday

    Some investors booked profits following the company's recent cystic fibrosis trial data.

  • Simply Wall St.2 months ago

    Is Proteostasis Therapeutics Inc (NASDAQ:PTI) Worth US$10.35 Based On Intrinsic Value?

    In this article I am going to calculate the intrinsic value of Proteostasis Therapeutics Inc (NASDAQ:PTI) by taking the expected future cash flows and discounting them to today’s value. I Read More...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Endocyte

    NEW YORK, NY / ACCESSWIRE / October 19, 2018 / Shares of biotech stocks Proteostasis Therapeutics and Endocyte were seeing big gains on different exciting announcements. Proteostasis announced encouraging preliminary results while traders learned that Endocyte will be purchased by Novartis for $2.1 billion. Proteostasis Therapeutics, Inc. shares closed up 447.62% on Thursday on skyrocket volume of about 94 million shares.

  • PTI Stock News: Why Is Proteostasis Therapeutics Stock Skyrocketing Today
    InvestorPlace2 months ago

    PTI Stock News: Why Is Proteostasis Therapeutics Stock Skyrocketing Today

    The preliminary clinical trial results sending PTI stock higher today concern Proteostasis Therapeutics’ (NASDAQ:PTI) therapies to treat cystic fibrosis and other dysfunctional protein processing diseases. The preliminary results are for tests involving PTI-808, PTI-801, and PTI-428. According to Proteostasis Therapeutics, the goal of its recent clinical trials is to determine the safety, tolerability, and pharmacokinetics of the three drugs.

  • Benzinga2 months ago

    Proteostasis Therapeutics Shares Surge On Positive Preliminary Cystic Fibrosis Trial Results

    Biotech Proteostasis Therapeutics Inc. (NASDAQ: PTI) develops therapeutics for the treatment of cystic fibrosis and associated disorders. Proteostasis shares were surging 300 percent on the announcement of positive preliminary results from three doublet cohorts of Phase 1 placebo-controlled studies in subjects with cystic fibrosis.

  • MarketWatch2 months ago

    Proteostasis Therapeutics' rockets to 4-fold gain on massive volume after positive trial results

    Shares of Proteostasis Therapeutics Inc. blasted off to a four-fold gain (up 301%) on extremely heavy volume after the biopharmaceutical company announced positive results from a phase 1 trial of its cystic fibrosis treatment. Volume spiked to over 44 million shares, compared with the full-day average of 152,000 shares. The company said changes in sweat chloride concentration and in percent predicted FEV (ppFEV) were assessed, and dose-dependent improvements were observed. For ppFEV, "a maximum and statistically significant increase" from baseline was reported, and a "statistically significant" increase from placebo was also noted. "These data are the first results seen using an entirely new CF doublet, compare favorably to standard of care, and demonstrate the potential of next-generation CFTR modulators to further improve outcomes in this disease," said Carsten Schwarz, head of the Adult Cystic Fibrosis Centre at Berlin University. The stock had tumbled 67.6% year to date through Wednesday, while the S&P 500 had gained 5.1%.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 17) Anixa Biosciences Inc (NASDAQ: ANIX ) Down In The Dumps ...

  • PR Newswire2 months ago

    Proteostasis Therapeutics Announces Positive Preliminary Results from Proprietary Doublet in Cystic Fibrosis Patients

    BOSTON, Oct. 17, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced positive preliminary results from three doublet cohorts of the Company's ongoing Phase 1, randomized, double-blind, placebo-controlled studies of the Company's proprietary combination therapy doublet, PTI-808 and PTI-801, and an enrollment update from the triplet, PTI-808, PTI-801, and PTI-428, in subjects with cystic fibrosis.

  • Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options

    Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Ares Commercial Real Estate, Proteostasis Therapeutics, SunCoke Energy Partners, Fastenal, CNA Financial, and City Office REIT — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Sept. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • PR Newswire3 months ago

    Proteostasis Therapeutics to Present at the Cantor Global Healthcare Conference

    BOSTON, Sept. 27, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Marija Zecevic, Ph.D., the Company's Chief Operating Officer, will present at the Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 3:25 p.m. ET at the InterContinental New York Barclay. A live audio webcast of the Cantor Global Healthcare Conference presentation will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com. A replay of the webcast will be available on the Company's website following the presentation.

  • PR Newswire6 months ago

    Proteostasis Added to the Russell 3000® Index

    BOSTON, June 25, 2018 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced that the Company's stock was added to the Russell 3000® Index when the Russell Investment Group reconstituted its family of U.S. indexes following market close on June 22, 2018. "Inclusion in the Russell 3000 Index increases liquidity and raises visibility for PTI among a broader group of investors at a time where we anticipate reaching multiple clinical milestones for our novel cystic fibrosis transmembrane conductance regulator (CFTR) modulators," said Meenu Chhabra, President and Chief Executive Officer of Proteostasis.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Ophthotech Corporation

    NEW YORK, NY / ACCESSWIRE / June 8, 2018 / While Proteostasis Therapeutics announced positive results from an ongoing 14-day dosing study of PTI-801, an analyst at RBC Capital Markets didn't seem impressed and downgraded the company this week as well as lowered his price target on shares. Ophthotech Corporation saw a different story yesterday, gaining over 10% after announcing that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania. The results had shown statistically significant improvement in sweat chloride, body mass index, and weight and blood glucose.

  • Proteostasis Therapeutics (PTI) Enters Oversold Territory
    Zacks6 months ago

    Proteostasis Therapeutics (PTI) Enters Oversold Territory

    Proteostasis Therapeutics, Inc. (PTI) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock